Milestone Scientific Inc. Commences Sales of CompuFlo® / CathCheck™ Disposables to the Nationally Recognized Medical University of South Carolina
March 2, 2021 9:30 am
ROSELAND, N.J., March 02, 2021 — Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, today announced it has begun selling CompuFlo® / CathCheck™ disposables to the Medical University of South Carolina (MUSC). The MUSC University Medical Center is a nationally recognized and leading health sciences university, recently ranked as the number one hospital in South Carolina. MUSC Health owns and operates eight hospitals and provides patient care throughout the state of South Carolina.
Arjan Haverhals, President of Milestone Scientific, further noted, “We appreciate the support of Dr. Hebbar, Director Obstetrics Anesthesia, and her team at MUSC. This latest commercial order follows extensive testing on the part of the MUSC team. This decision by another leading U.S. medical center further illustrates the favorable response to both CathCheck and CompuFlo as we execute on our goal to become the new standard of care in epidural procedures.”
The clinical and safety benefits of the CompuFlo Epidural / CathCheck System are backed by extensive published clinical data demonstrating significant reductions in epidural punctures, as well as complication rates, and contributes to savings of time on the part of anesthesiologists. Moreover, the CompuFlo instrument has the potential to significantly reduce costs associated with morbidity, providing a direct economic benefit to healthcare institutions. Similarly, the CathCheck technology has the potential to transform the monitoring of catheter placement following an epidural procedure by confirming the placement of a catheter within 2 minutes, versus 20-40 minutes using conventional methods.
About the Medical University of South Carolina (MUSC)
Founded in 1824, the Medical University of South Carolina (MUSC) continues the tradition of excellence in education, research and patient care. MUSC educates and trains more than 3,000 students and nearly 800 residents in six colleges and has more than 17,000 employees. As the state’s only integrated academic health sciences center and largest non-federal employer in Charleston, the university and its affiliates have collective annual budgets in excess of $3.2 billion, with an annual economic impact of nearly $4 billion and annual research funding in excess of $284 million.
As the clinical health system of the Medical University of South Carolina, MUSC Health is dedicated to delivering the highest quality patient care available, while training generations of competent, compassionate health care providers to serve the people of South Carolina and beyond. Comprising some 1,600 beds, more than 100 outreach sites, the MUSC College of Medicine, the physicians’ practice plan, and nearly 275 telehealth locations, MUSC Health owns and operates eight hospitals situated in Charleston, Chester, Florence, Lancaster and Marion counties. In 2020, for the sixth consecutive year, U.S. News & World Report named MUSC Health the No. 1 hospital in South Carolina.
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs and develops innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone’s computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone’s proprietary DPS Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website: www.milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone’s ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone’s control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone’s periodic filings with the Securities and Exchange Commission, including without limitation, Milestone’s Annual Report for the year ended December 31, 2019. The forward-looking statements in this press release are based upon management’s reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
David Waldman or Natalya Rudman
Crescendo Communications, LLC